Skip to main content
Menu
Revvity logo
Contact us
US
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Login/Register here
Revvity web shop online account

Get exclusive pricing on all online purchases.

Login to your Revvity.com account for your account's pricing, easy re-ordering from favorites & order history, priority order processing, and dynamic order tracking.

Login Register
Revvity Omics portal accounts

Initiate a new order or access test status and results for clinical genomics or newborn screening services.

View login options
Breadcrumb
...
  • Home
  • Services
  • Preclinical Services
    • Preclinical Services
    • Revvity Omics Services
    • Clinical & Testing Services
    • Customization Services
    • Licensing
    • Viral Vector Engineering and Manufacture
    • Instrument Service & Maintenance
    • Customer Training
    • OEM Solutions
  • Base Editing Platform
    • Antibody Drug Conjugate Services
    • Complex Cell Model Screening Services
    • Base Editing Platform
    • Immune Cell Screening
    • Functional Genomic Screening Services
    • Cell Panel Screening
    • Cell Line Engineering
    • Viral Vector Engineering and Manufacture
  • Pin-point base editing platform pooled tiled screening services
    • Pin-point base editing platform cell line engineering services
    • Pin-point base editing platform pooled tiled screening services

Pin-point Base Editing Platform Pooled Tiled Screening Services

Accelerate single-base screening with Pin-point base editing platform services

If you want to take advantage of the novel Pin-point™ Base Editing platform for next-generation screening applications but don’t have the in-house resources, you can now leverage our internal expertise. Our team of scientists will work with you to generate high-quality, reproducible data that you can trust.


The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
 

Contact us
pooled-tiled-screening-services872x872.jpg
""

Explore our solutions

Functional genomic screening with the Pin-point base editing platform How do pooled tiled base editing screens work? See example screen data What's included

Functional genomic screening with the Pin-point base editing platform

Base editing with the Pin-point platform provides precise, controlled changes in target sequences with lower potential for on- or off-target DNA damage and healthier cell outcomes, even in sensitive cell types.

pnp-model-3-generic

In the Pin-point base editing platform configuration used in our functional genomics screens, a nickase Cas9 (nCas9) component is recruited to the DNA target sequence via a single guide RNA (sgRNA) encoding an aptamer in the scaffold region. The aptamer recruits a DNA-modifying deaminase to the DNA target sequence via an aptamer binding protein. The three independent components of the system can be configured according to editing requirements and delivered to cells either as mRNA, or packaged in viral vectors.

Modify up to every PAM-accessible cytidine in the gene of interest to gain unparalleled understanding of the genotype-phenotype relationship

As part of our functional genomic screening services, we can partner with you on tiled base editing screens with the Pin-point platform. These tiled base editing screens can be used to interrogate every accessible cytosine in a DNA sequence by generating precise C-to-T mutations. This information can then be used to select the best guide RNA(s) for potential therapeutic applications, identify critical amino acids in structure-function analysis, or to test ligand binding relationships in drug candidate screening and confirm target identity.

With FGS and Pin-point base editing, you can:

  • Target splice sites and introduce premature stop codons to recapitulate CRISPRko and CRISPRi screens.
  • Identify novel hits by the introduction of missense mutations that may not be possible to reveal with parallel methods.
  • Include functional loss or enhancement mutations in a single screen to elucidate possible mechanisms of drug sensitivity and resistance or protein function.
  • Utilize different deaminases to maximize the editing window and evaluate more of the genetic sequence.
  • Leverage our data analysis to generate hit lists and potentially identify putative causative mutations.
  • Explore drug-gene interactions for sensitivity and resistance, and illuminate unique functional protein domains.

Our services team has broad expertise in CRISPR-based pooled screens and has directly been involved in the development of the Pin-point base editing platform, so are uniquely positioned to support you.

How do pooled tiled base editing screens work?

slide-tiled-ms2

The Pin-point platform components are stably transduced into cells expressing either the rat or anolis APOBEC deaminase. A library of sgRNAs that include a sensor element with its corresponding target sequence are delivered into cells with lentivirus at high coverage. The presence of the sensor allows for the measurement of the editing that could be achieved at the endogenous locus by NGS in a pooled screen format. After selection for the sgRNAs, cells are challenged with the compound to be tested (e.g. vemurafenib) at an IC20 or IC80 dose to determine perturbations that confer sensitivity or resistance to the drug. Throughout the screen, samples are taken for subsequent NGS analysis to determine the levels of editing achieved and the loss or enrichment of the guide sequences.

See example screen data

pin-point-tiled-screening-data-figure

A. Endpoint data of the IC80 screen showing enrichment of guides that confer resistance to the drug correlating with increased levels of editing. B. Comparison of editing levels of guides shown to confer resistance between the start and end of the screen, shows strong enrichment for edited genomes. The enrichment is more pronounced in the presence of the Pin-point platform configured with anolis APOBEC, where initial editing levels are higher. Loss of expression of the Neurofibromin 1 (NF1) has previously been reported to confer BRAFi resistance. C. Data demonstrates that guides resulting in NF1 knockout by targeting either the mRNA slice sites or introducing nonsense mutations in the NF1 mRNA are more likely to confer drug resistance when compared to guides introducing missense mutations. D. Identified missense mutations that confer resistance show no hotspot regions in the NF1 gene, which is in agreement with clinical observations. Multiple guides introducing the same resistance conferring mutation are shown to demonstrate similar screen phenotypes.

What's included

  • Tiled guide RNAs for C-to-T base changes across an entire gene, amplicon, or other custom target region of your choice.
  • Tune the Pin-point base editing platform for focused or broad editing windows.
  • Stable or transient expression of base editing components.
  • Custom guide RNA libraries designed by our team of experts to your target region(s) of interest.
  • Each custom pooled library is quality checked for representation, distribution, and particle titer to ensure consistent results.
  • Readout of editing outcome for each gRNA via internal sensor sequence.
  • Next-generation sequencing reporting with bioinformatic analysis and hit nominations.
  • Increased cell health:
    • Perturbations are introduced while avoiding dsDNA breaks, leading to less cytotoxicity, particularly in sensitive cell types.
    • Edit cells that are typically sensitive to DNA damage in wild type CRISPR studies.

Featured resources

Brochure

The Pin-point™ platform: A novel modular base editing system

Learn more
line

Questions?
We’re here to help.

Contact us
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.